Kura Oncology's Darlifarnib + Adagrasib Shows Strong Clinical Activity in KRAS G12C Solid Tumors, ORRs Up to 67%
KURA has more than doubled off its 52-week low of $5.45.
Summary
Kura Oncology reported compelling Phase 1a clinical data for its drug darlifarnib in combination with adagrasib for KRAS G12C-mutated solid tumors, demonstrating strong clinical activity and a manageable safety profile. Objective response rates (ORRs) were 67% in pancreatic ductal adenocarcinoma (PDAC), 50% in non-small cell lung cancer (NSCLC), and 29% in KRASi-naïve colorectal cancer (CRC), with 77% of response-evaluable patients achieving tumor shrinkage. This follows previous positive preliminary data for darlifarnib in combination with another agent reported on April 17th, further advancing Kura's lead pipeline asset. These are significant efficacy numbers for heavily pretreated patients in difficult-to-treat cancers, particularly PDAC, de-risking the darlifarnib program and highlighting its potential as a combination therapy. The full results will be presented at the ASCO Annual Meeting on May 30, 2026, with a virtual investor event on June 3, 2026.
At the time of this announcement, KURA was trading at $11.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $998.7M. The 52-week trading range was $5.45 to $12.49. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.